Welcome and Opening Remarks Todd C. Brady, M.D., Ph.D., Chief Executive Officer

ADX-629: A First-in-Class, Oral

RASP Modulator for the Treatment of Systemic Disease 2022 Research & Development Day March 29, 2022 Nasdaq: ALDX Aldeyra Therapeutics, Inc. 2022 Exhibit 99.1

Welcome and Opening Remarks Todd C.

Brady, M.D., Ph.D., Chief Executive Officer March 29, 2022 Nasdaq: ALDX Aldeyra Therapeutics, Inc. 2022

Disclaimers and Forward-Looking

Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act

of 1934, as amended, including statements regarding Aldeyra's possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, political, economic,

legal, social and health risks, including the COVID-19 pandemic and related public health measures and other responses to it, that may affect Aldeyra's business or the global economy, the structure, timing and success of Aldeyra's

planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. The results of earlier or

smaller preclinical or clinical trials may not be predictive of future results. As a result of the COVID-19 pandemic, clinical site availability, staffing, and patient recruitment have been negatively affected and the timelines to complete

Aldeyra's clinical trials may be delayed. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "may," "might," "will,"

"objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target,"

"design," "estimate," "predict," "potential," "plan" or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and

other factors that may cause Aldeyra's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect

Aldeyra's current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including the development, clinical and regulatory plans or expectations for Aldeyra's product candidates and

systems-based approaches, later developments with the FDA that may be inconsistent with Aldeyra's expectations and beliefs, including the risk that the results from earlier clinical trials, portions of clinical trials, or pooled clinical data

may not accurately predict results of subsequent trials or the remainder of a clinical trial for the same or different indications, inconsistent expectations regarding FDA acceptance and review of the company's filings and submitted data sets,

and Aldeyra's continuing review and quality control analysis of clinical data, including P values. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements are

described in Aldeyra's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as Aldeyra's subsequent filings with the Securities and Exchange Commission. All of Aldeyra's development plans and timelines may be

subject to adjustment depending on funding, recruitment rate, regulatory review, preclinical and clinical results, and other factors any of which could result in changes to Aldeyra's development plans and programs or delay the initiation,

completion, or reporting of clinical trials. In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be

guaranteed, and actual results may differ materially from such statements. The information in this presentation is provided only as of March 29, 2022, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this

presentation on account of new information, future events, or otherwise, except as required by law.

Agenda 4 TIME (ET) TOPIC PRESENTER

10:00 - 10:15 a.m. RASP Overview Todd C. Brady, M.D., Ph.D. Chief Executive Officer, Aldeyra Therapeutics 10:15 - 10:45 a.m. RASP and Inflammation Geoffrey M. Thiele, Ph.D. Umbach Professor, Internal Medicine, University of Nebraska

Medical Center 10:45 - 11:15 a.m. ADX-629 in In vivo and In vitro inflammatory models Michael J. Duryee, MS Instructor, Internal Medicine, University of Nebraska Medical Center 11:15 - 11:30 a.m. Questions 11:30 - 11:40 a.m.

Break 11:40 - 11:50 a.m. Preclinical Activity of ADX-629 Adam Brockman, Ph.D. Director of Translational Science, Aldeyra Therapeutics 11:50 - 12:20 p.m. Proof-of-Concept Top-Line Data Todd C. Brady, M.D., Ph.D. 12:20 - 12:35 p.m.

New Molecules, New Indications Adam Brockman, Ph.D. 12:35 - 12:55 p.m. Questions 12:55 - 1:00 p.m. Concluding Remarks Todd C. Brady, M.D., Ph.D.

ALDEYRA'S MISSION is to discover

and develop innovative medicines that improve the lives of patients who suffer from immune-mediated diseases. OUR APPROACH is to create therapies that modulate immunological systems, instead of directly inhibiting or activating single protein

targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. VISION For our Drug Development Platform

PRODUCT CANDIDATES DISEASE TARGETS

DEVELOPMENT STAGE NEXT EXPECTED MILESTONE RASP PLATFORM FOR OCULAR AND SYSTEMIC IMMUNE-MEDIATED DISEASES Reproxalap (ophthalmic solution) Dry Eye Disease Phase 3 Mid-2022: Final Pivotal Trial Results Allergic Conjunctivitis Phase 3 2023: Final

Pivotal Trial Results ADX-629 (oral administration) Ethanol Toxicity, Chronic Cough, Sj gren-Larsson Syndrome, Minimal Change Disease Phase 2a 2022 and 2023: Trial Completion RASP-Modulator Discovery Platform Multiple Immune-Mediated Retinal

and Systemic Indications Preclinical 2023: IND Submission VITREOUS METHOTREXATE PLATFORM FOR RARE RETINAL INFLAMMATORY DISEASES ADX-2191 (intravitreal injection) Primary Vitreoretinal Lymphoma (U.S. FDA Orphan Drug Designation) Pre-NDA H2 2022:

Regulatory Update Proliferative Vitreoretinopathy (U.S. FDA Orphan Drug and Fast Track Designation) Phase 3 H2 2022: Part 1 GUARD Trial Results Retinitis Pigmentosa (U.S. FDA Orphan Drug Designation) Phase 2 H2 2022: Trial Results Aldeyra is a

Well-Capitalized Biotechnology Company with a Broad Immunology Pipeline and Near-Term Catalysts As of 12/31/2021, cash and cash equivalents were $229.8M, which is expected to be sufficient to fund operations through the end of 2023, based on

projected operating expenses. Company guidance as of March 17, 2022. IND = Investigational New Drug. NDA = New Drug Application.

RASP are formed by a variety of

metabolic processes, including: glucose metabolism, alcohol oxidation, lipid peroxidation, and polyamine metabolism. Reactive Aldehyde Species (RASP) RASP are eliminated by chemical and enzymatic means: biomolecular adduction (thiol and amine

covalent binding) and aldehyde dehydrogenases and reductases. Drugs Metabolism & Lipid Peroxidation Smoking & Vaping Food & Beverages Pollution Endogenous aldehyde sourced within the body Inflammation Exogenous aldehyde sourced outside

RASP Induce Inflammation via Multiple

Mechanisms RASP Aldehydes covalently bind thiol (Michael addition) and amine (Schiff base) residues on proteins. Direct protein binding leads to conformational and functional changes in proteins, which in turn initiate a pro-inflammatory signaling

cascade. Aldehyde-protein adducts are ligands for Scavenger Receptor A, subsequently leading to autoantibody formation against the adducted protein. Receptor / Kinase Modification Scavenger Receptor A Binding Protein Signaling via Binding to Thiols

and Amines Inflammasome, NF-kB Activation, Cytokine Release Autoantibody Formation

RASP Signaling is Mediated by

Covalently Binding Proteins Lipid-derived aldehydes such as malondialdehyde (MDA), hydroxynonenal (HNE), and acrolein are the most studied regarding inflammatory signaling MDA HNE Acrolein Michael adduct Schiff base crosslink Cysteine thiols are the

most sensitive to aldehyde adduction, followed by the amines of lysine and histidine. HNE

The Pro-Inflammatory RASP Signaling

Cascade is Well Characterized RASP signaling occurs via adduction to kinases and receptors. Both pathways communicate cell surface signals to the nucleus, leading to the expression of transcription factors including AP-1 and NF-KB. IKB - IkB

kinase AP-1 - activator protein 1 PKC - protein kinase C MAPK - mitogen-activated protein kinase EGFR - epidermal growth factor receptor ERK - extracellular signal-regulated kinase NF-KB - nuclear factor of

kappa-light-chain-enhancer of activated B cells Cytokine Production NF-KB AP-1 Mitogen ERK MAPK EGFR Inflammation Plasma membrane Inhibition Inhibition IKB PKC RASP Nuclear membrane

RASP Signaling is Fundamentally

Different from Receptor Signaling RASP activity represents a novel pro-inflammatory signal transduction paradigm, distinct from ligand/receptor interactions. MECHANISM BOND OUTPUT MEMORY RASP Covalent Analog Pluripotent and contingent on adduct

levels Solid-State Outcome dependent on prior adduct levels Ligand/ Receptor Ionic, Hydrogen Digital Unipotent and contingent on binding or no binding Flash Outcome independent of prior binding state RASP modulation is one of the few examples of

pharmacologic therapies that do not directly target proteins and do not effect digital outcomes. Source: Higdon A, Diers AR, Oh JY, Landar A, Darley-Usmar VM. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem

J. 2012 Mar 15;442(3):453-64.

Aldeyra is Developing Technology

Designed to Modulate Biological Systems Not Single Targets TRADITIONAL PHARMACOLOGY IS LIMITED TO TWO OUTCOMES Most immunological drugs shut down specific molecules, obstructing the immune system and leading to toxicity.

Aldeyra is Developing Technology

Designed to Modulate Biological Systems Not Single Targets SYSTEMS-BASED PHARMACOLOGY ALLOWS FOR INFINITE CONTROL In contrast, modulation of the immune system maintains immune function, but allows for lower levels of inflammation.

Aldeyra is One Pivotal Trial Away

from NDA Submission of Reproxalap for Allergic Conjunctivitis NDA submission requirements depend, in part, on clinical results and regulatory feedback. Source: INVIGORATE clinical trial results. Topical ocular reproxalap has been

studied in more than 1,500 patients with no observed safety concerns; mild and transient instillation site discomfort is the most commonly reported adverse event in clinical trials. MMRM = mixed model repeated measures. Minutes in Allergen Chamber

First Dose Prior to Chamber Entry Key Secondary Endpoint Reduction in Ocular Redness Over the Entire Chamber Mean Ocular Redness Score (0-4) MMRM p < 0.0001 Second Dose Vehicle Reproxalap Minutes in Allergen Chamber Primary Endpoint Assessment

Period for Statistical Significance of Majority of Time Points All p values < 0.0001 Second Dose First Dose Prior to Chamber Entry Primary Endpoint Reduction in Ocular Itching Over Pre-Specified Time Frame Mean Ocular Itching Score (0-4)

Reproxalap Vehicle 250 1.6 1.4 1.2 1.0 0.8 0 050100150200250 The Phase 3 INVIGORATE Allergen Chamber Trial

NDA submission requirements

depend, in part, on clinical results and regulatory feedback. Draft U.S. Food and Drug Administration (FDA) guidance. *Adequate and well-controlled Phase 2 or Phase 3 clinical trials can be submitted as pivotal. #Schirmer test was a secondary

endpoint in the TRANQUILITY Trial. Sources: Clinical trial results on file. MMRM = mixed model repeated measures. SEM = standard error of the mean. Topical ocular reproxalap is an investigational drug candidate that has been studied in more than

1,500 patients with no observed safety concerns; mild and transient instillation site discomfort is the most commonly reported adverse event in clinical trials. Aldeyra is One Pivotal Clinical Trial Away from NDA Submission of Reproxalap for

Dry Eye Disease Aldeyra intends to submit two previously completed 12-week adequate and well-controlled symptom trials that pre-specified patient-reported ocular dryness score as a primary endpoint or a co-primary endpoint. Symptoms Signs

Aldeyra has shown statistically significant results in ocular redness in the Phase 2* dry eye chamber trial and in Schirmer test in the Phase 3 TRANQUILITY Trial#. Both ocular redness and Schirmer test are FDA-sanctioned, objective signs of dry eye.

To satisfy efficacy requirements for dry eye disease, the FDA requires two positive trials with the same symptom and two positive trials with the same sign.

Topical ocular reproxalap is an

investigational drug candidate that has been studied in over more than 1,500 patients with no observed safety concerns; mild and transient instillation site discomfort is the most commonly reported adverse event in clinical trials. The Activity of

Lead RASP Modulator Reproxalap is Supported by Marquee Peer-Reviewed Publications

Reactive Aldehyde Species and

Inflammation: Evidence for Malondialdehyde and Acetaldehyde as Pro-Inflammatory Mediators Geoffrey M. Thiele, Ph.D. Umbach Professor of Rheumatology Department of Internal Medicine Division of Rheumatology and Immunology

Adam Brockman, Ph.D., DABT, Director

of Translational Science Preclinical Activity of ADX-629 in Models of Inflammation Nasdaq: ALDX Aldeyra Therapeutics, Inc. 2022 March 29, 2022

In a Murine Model of Cytokine Storm,

ADX-629 Broadly Reduced Inflammatory Cytokines and Increased IL-10 Endotoxin model of cytokine storm ADX-629 100mg/kg administered intraperitoneally 15 minutes prior to endotoxin TH1, TH2, TH17 down-regulation in addition to up-regulation of the key

anti-inflammatory cytokine, IL-10 **p 0.01, ****p 0.001

ADX-629 Treatment Reduced Cellular

Infiltrate in a Murine Model of Acute Respiratory Distress Syndrome (ARDS) Endotoxin model of ARDS ADX-629 120mg/kg administered orally two hours prior to endotoxin Increased percentages of macrophages and decreased neutrophils in

bronchoalveolar lavage fluid Increase is Favorable Decrease is Favorable

ADX-629 Reduced Disease Activity

Index Score in Murine Model of Ulcerative Colitis Dextran sulfate sodium model of ulcerative colitis ADX-629 100mg/kg administered intra-peritoneally daily for 6 days Statistical reduction in disease activity index

In a Rat Model of Nephritis, ADX-629

Reduced Proteinuria Puromycin aminonucleoside (PAN) model of nephritis ADX-629 250mg/kg administered orally twice daily for 13 days Statistical reduction in proteinuria at 7 and 13 days

Todd C. Brady, M.D., Ph.D., Chief

Executive Officer ADX-629 Proof-of-Concept Top-Line Clinical Trial Data Nasdaq: ALDX Aldeyra Therapeutics, Inc. 2022 March 29, 2022

1 Phase 2 clinical trial in COVID-19

ADX-629, a RASP Modulator for Oral Administration, Is a First-in-Class Pharmacologic Approach and Highlights the Future of Aldeyra ADX-629 is an investigational first-in-class, orally available covalent modulator of pro-inflammatory RASP, and

potentially represents a new paradigm in the understanding and treatment of systemic immune-mediated disease. A comprehensive systemic disease initiative was implemented to assess the activity of ADX-629 in three types of severe inflammation:

autoimmune disease; allergic inflammation, and infectious disease. Phase 2 Proof-of-Concept, Indication-Selecting Clinical Trials in Three Types of Severe Inflammation RASP-MODULATION IN SYSTEMIC DISEASES Autoimmune Disease 2 Phase 2

allergen-challenge clinical trial in atopic asthma Allergic Inflammation Infectious Disease 3 Phase 2 clinical trial in psoriasis

RASP LEVELS OVER 10 DAYS OF DOSING

ADX-629 Reduced RASP vs. Placebo in Phase 1 Clinical Trial, Demonstrating Target Engagement, and Improved Lipid Profiles PLASMA LIPID PROFILE AFTER FATTY MEAL p = 0.005 p = 0.036 p = 0.0004 HDL (mg/dL AUC) LDL/HDL ratio (AUC) FFA (mM AUC) Source: